Spurring Innovative Rare Disease Drug Development

Infographic | December 1, 2019

Rideshare companies like Uber and Lyft challenged the old way of doing things with a new approach. It’s not just about getting from point A to point B anymore, it’s about the experience, convenience and added value. The same applies to pass-through PBMs (pharmacy benefit managers) that are challenging the status quo to make prescriptions more affordable..

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Infographic | June 3, 2022

Pharma Technology Focus is free to read on all devices.

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Infographic | February 5, 2020

A type of immunotherapy in which T cells are given to a patient to help the body fight diseases. In cancer therapy, T cells are usually taken from the patient’s own blood or tumor tissue, grown in large numbers in the laboratory, and then given back to the patient to help the immune system fight the cancer.

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.